poisar

Stock

SAB Biotherapeutics, Inc. SABS

$3.92+1.29%

Overview

SABS market data

Price History

SABS price chart · 1M
O
3.88
H
3.92
L
3.85
C
3.92
Vol
23,576.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$3.88
Previous Close
$3.87
Day High
$3.92
Day Low
$3.85
52 Week High
$4.58
52 Week Low
$3.29
7 Day Return
+6.23%
30 Day Return
+13.29%
90 Day Return
+9.04%
1 Year Return
+12.00%
Daily Notional Volume
$92.4K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
26.12
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$0.22
Diluted earnings per share over the trailing twelve months.
Beta
0.60
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-1,795.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.85 – $5.15
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $346.7M · P/B 1.18 · P/S 262.06.

Company News

6 captured
SAB Biotherapeutics Q2 2026, Cash Balance Of $208.0M, Providing Runway Through 2028Benzinga · Aug 6, 2026, 11:36 AM
SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 DiabetesBenzinga · Jul 7, 2026, 12:20 PM
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13Benzinga · Jun 24, 2026, 6:55 PM
Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16Benzinga · Jun 17, 2026, 12:40 PM
Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jun 15, 2026, 2:00 PM
Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12Benzinga · Jun 15, 2026, 1:05 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock